Subodh Verma

Professor Subodh Verma is a globally recognized cardiac surgeon-scientist whose pioneering and interdisciplinary contributions have transformed the landscape of cardiovascular science, surgery and cardiometabolic medicine in Canada and around the world. He is Professor of Surgery, and Pharmacology & Toxicology at the University of Toronto, and holds a Tier 1 Canada Research Chair in Cardiovascular Surgery. With over 800 peer-reviewed publications, a Google Scholar h-index of 144 and over 110,000 citations in February 2026, Dr Verma ranks among the top 0.1% of highly cited researchers globally. He has played a key role in landmark clinical trials, including all five pivotal SGLT2 inhibitor studies in heart failure and several GLP-1 receptor agonist trials in peripheral artery disease, atherosclerosis and HFpEF.

Dr Verma recently received the 2025 Canadian Cardiovascular Society Research Achievement Award – Basic and Translational Science and the 2025 Canadian Society of Cardiac Surgeons Achievement Award. He is a past recipient of the University of Toronto Lister Prize, the Howard Morgan Award from the ISHR, the Royal College Gold Medal and the Alumnus of Distinction Award from the University of Calgary. He founded the CardioLink Trials Platform, Canada’s first and to date only translational clinical trials infrastructure dedicated to cardiac surgery and cardiometabolic science. His groundbreaking discovery of human vascular stem cell exhaustion has unlocked novel mechanistic insights into atherosclerosis, obesity and diabetes—bridging high-impact human biology with clinical care.

Dr Verma serves as the Editor-in-Chief of Current Opinion in Cardiology and is an Associate Editor for the Journal of Thoracic and Cardiovascular Surgery, European Journal of Cardiothoracic Surgery and the European Journal of Heart Failure as well as a Guest Editor for Circulation and Journal of the American College of Cardiology. He is the current Scientific Program Chair for the Canadian Society of Cardiac Surgeons, where he continues to promote academic and clinical excellence across the surgical community.